Dr Reddy’s successful phase I study of biosimilar to Genentech’s Actemra® (tocilizumab)

Jun 5, 2023

Dr Reddy’s Laboratories announced completion of a successful phase I clinical trial of DRL_TC, its biosimilar to Genentech’s Actemra® (tocilizumab) by intravenous route.  The study demonstrated the pharmacokinetic equivalence, safety, and immunogenicity of DRL_TC compared to the reference products (US sourced Actemra® and EU sourced RoActemra®), confirming similarity in pharmacodynamic parameters and no notable differences in safety and immunogenicity.

In December 2022, Dr Reddy’s announced successful phase I trial of DRL_TC by subcutaneous route.

Print Page Mail Article